News

Kenox Contributes to New Research on Respimat® Soft Mist Inhaler, Published in Pulmonary Therapy

Back

Princeton, NJ – Kenox Pharmaceuticals Inc. (Kenox)

We are proud to share that our latest research collaboration article with Boehringer Ingelheim, “Impact of Flow Restrictors on Aerosol Delivery of the Respimat® Soft Mist Inhaler,” has been published in Pulmonary Therapy!

Co-authored by Sitaram Velaga and David Stadermann of Kenox Pharmaceuticals, the paper explores how flow restrictors can influence aerosol performance, spray dynamics, and deposition of soft mist inhalers. The study provides valuable insights into optimizing inhaler design to improve patient outcomes.

This publication highlights Kenox’s continued commitment to advancing innovation in inhalation science and drug delivery technologies.

👉 Read the full article in Pulmonary Therapy